HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Early detection, trial participation keys to improved outcomes in pancreatic cancer
-
- FDA approves Alprolix for hemophilia B
- FDA approves Pradaxa to treat DVT, PE
- 24-month EFS predicted OS in diffuse large B-cell lymphoma
- Cancer stem cell number may not predict outcomes in HPV-associated HNSCC
- CAR T-cell therapy induced high complete response rate in advanced B-ALL
- Concomitant boost thoracic radiation plus chemotherapy benefited NSCLC patients
- Many physicians lack confidence interpreting genomic test results
- Patients with mRCC preferred pazopanib to sunitinib
-
- Stage 4N neuroblastoma tumors may require less intensive therapy
- Trastuzumab showed moderate benefit in HER-2–negative breast cancer
- CDK inhibitor shows promise in metastatic breast cancer
- Sun exposure, family history guide risk assessment for melanoma screening
- Standards needed to guide technology’s role in skin imaging
- Novel small molecule inhibitor shows promise in hematologic malignancies
- Researchers identify breast cancer subtype that may benefit from neratinib